Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

已取消 10 由慕月发布于 2025/8/26 16:43:32

DOI:10.1016/S0140-6736(19)32517-6
作者：Stephen A Harrison
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1016/S0140-6736(19)32517-6

Elsevier

Abstract：Background: Non-alcoholic steatohepatitis (NASH) is characterised by hepatic steatosis, inflammation, hepatocellular injury, and progressive liver fibrosis. Resmetirom (MGL-3196) is a liver-

应助信息

2025-08-26

Book学术机器人

2025/8/26 16:43:32 未找到该文献，机器人已退出，请等待人工下载

2025/8/26 16:43:32 Book学术AI机器人收到请求，开始寻找文献

2025/8/26 16:43:32 已向机器人发送请求

2025-08-26

慕月发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierPrimary exothermic reaction pathways between solid electrolyte interphases and electrolytes during the onset of thermal runaway in lithium-ion batteries